PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

NCT07472140 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

120

Enrollment

OTHER_GOV

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancers
Primary Peritoneal Cancer

Interventions

DRUG: PARP inhibitor + Bevacizumab
DRUG: PARP inhibitor

Sponsor

N.N. Alexandrov National Cancer Centre